BioAtla Inc. (NASDAQ: BCAB) announced it will implement a 50-for-1 share consolidation of its common stock, effective April 6, 2026 at 12:01 a.m. Eastern Time. The biotechnology company's stock will continue trading on The Nasdaq Capital Market under the symbol "BCAB" on a split-adjusted basis when the market opens April 6.

The share consolidation aims to increase the per-share trading price to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing. Every 50 shares of outstanding common stock will automatically convert into one share following the consolidation.

BioAtla stockholders approved the consolidation plan at a special meeting held March 23, 2026. The consolidation will be executed through a merger between the company and its wholly-owned subsidiary, BA Merger Sub Inc., with BioAtla as the surviving entity.

No fractional shares will be issued in the consolidation. Stockholders who would receive fractional shares will receive cash equal to the fraction multiplied by the closing stock price on the effective date. The new CUSIP number for the common stock will be 09077B203.

The consolidation will proportionately reduce the number of shares available under the company's equity incentive and employee stock purchase plans. Exercise prices and share quantities for outstanding stock options and warrants will be adjusted accordingly. The par value of common stock and authorized share counts for common and preferred stock will remain unchanged.

Stockholders holding shares electronically or through brokers will have their positions automatically adjusted and are not required to take any action. BioAtla develops conditionally active biologic antibody therapeutics for solid tumor treatment and operates from San Diego, California.